Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study

Fig. 4

Head-to-head comparison of continuation with angiotensin receptor blockers vs. continuation with angiotensin-converting enzyme inhibitors, by different subgroups. Abbreviations: ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, CV cardiovascular. *Mediator-controlled hazard ratio (controlled direct effect): including systemic corticosteroids (excepting stratification by corticosteroids), anticoagulants, and immunomodulators

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us